Horizon Therapeutics announced the Brazilian Health Regulatory Agency, ANVISA, has approved Tepezza for the treatment of active TED. “Tepezza is the first and only medicine approved for active TED in Brazil, filling a significant unmet need for those who are living with this progressive autoimmune disease that can threaten vision,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HZNP:
- California, others join FTC challenge of Amgen deal to buy Horizon Therapeutics
- Jasper Therapeutics ap0points Brun to board of directors
- Horizon Therapeutics presents additional data from Phase 4 TEPEZZA trial
- Largest borrow rate increases among liquid names
- Horizon publishes new analysis from UPLIZNA N-MOmentum clinical trial